NewsStocksPHARMEXCIL Strengthens Government Partnership to Drive India's ₹30 Billion Pharma Export GrowthPHARMEXCIL Strengthens Government Partnership to Drive India's ₹30 Billion Pharma Export Growth
PHARMEXCIL has intensified government engagement through high-level meetings with Commerce, Pharmaceuticals, and DGFT officials to accelerate India's pharmaceutical export growth. India's pharma exports reached ₹30.47 billion in FY25 with 9.4% YoY growth despite global pricing pressures. The discussions focused on strengthening MSME participation through Chintan Shivir regional conferences, preparing for iPHEX 2026 exhibition, and leveraging the domestic market's projected growth from ₹60 billion to ₹130 billion by 2030 to support export expansion.
*this image is generated using AI for illustrative purposes only.
The Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) has stepped up its engagement with key government departments to chart the next phase of growth for India's pharmaceutical exports. The export promotion body conducted a series of strategic meetings in New Delhi with senior officials to discuss policy coordination, trade facilitation, and strengthening the sector's global competitiveness.
The PHARMEXCIL delegation, led by Chairman Namit Joshi, along with Nipun Jain (Chairman of iPHEX 2026 & MSME Committee) and Raja Bhanu (Director General), engaged with officials from the Department of Commerce and Industry, Department of Pharmaceuticals, and the Directorate General of Foreign Trade (DGFT). These discussions centered on policy alignment, innovation-led growth, and expanding MSME participation in pharmaceutical exports.
Strong Export Performance Despite Global Challenges
During meetings with Rajesh Agrawal, Secretary of the Department of Commerce and Industry, PHARMEXCIL presented India's robust pharmaceutical export performance. The sector demonstrated resilience with impressive growth metrics despite facing pricing pressures in key global markets.
| Performance Metric | FY25 Results |
|---|---|
| Total Exports | ₹30.47 billion |
| Year-on-Year Growth | 9.40% |
| Global Ranking | 4th among export promotion councils |
| Countries Served | Over 150 nations |
The export momentum has been supported by India's strong presence across multiple pharmaceutical segments, including generics, vaccines, and active pharmaceutical ingredients. PHARMEXCIL highlighted the sector's diversified demand base spanning both regulated and emerging markets, with the organization expressing optimism about surpassing previous year's performance levels in the current fiscal year.
Regional Outreach and MSME Integration
A significant focus of the government discussions was PHARMEXCIL's Chintan Shivir initiative, designed to strengthen regional pharmaceutical MSME engagement. This comprehensive program addresses critical areas for smaller manufacturers seeking to enter global markets.
The Chintan Shivir conferences cover essential topics including:
- Regulatory compliance frameworks
- International quality standards
- Export preparedness strategies
- Market access facilitation
Following a successful program in Chandigarh, PHARMEXCIL announced upcoming Chintan Shivir events planned for Ahmedabad and Hyderabad. The organization emphasized that regional outreach remains critical for broadening the exporter base and effectively integrating smaller manufacturers into global pharmaceutical supply chains.
iPHEX 2026: Global Pharmaceutical Showcase
The delegation briefed the Commerce Secretary on preparations for iPHEX 2026, India's flagship international pharmaceutical exhibition. This major industry event is scheduled for September 7-9, 2026, at Bharat Mandapam in New Delhi.
| Event Details | Specifications |
|---|---|
| Event Name | iPHEX 2026 |
| Dates | September 7-9, 2026 |
| Venue | Bharat Mandapam, New Delhi |
| Focus Areas | Buyer-seller interactions, regulatory engagement |
PHARMEXCIL positioned iPHEX as a key platform for showcasing India's pharmaceutical capabilities, facilitating crucial buyer-seller interactions, and strengthening engagement with global regulators and industry stakeholders. The upcoming edition aims to deepen India's footprint in regulated markets while expanding outreach to new geographical territories.
Domestic Market Growth Supporting Export Expansion
In discussions with Manoj Joshi, Secretary of the Department of Pharmaceuticals, PHARMEXCIL highlighted the sector's comprehensive growth trajectory. The organization presented compelling data showing how domestic market expansion supports export capabilities.
| Market Segment | Current Value | Projected Value (2030) |
|---|---|---|
| Export Market | ₹30.47 billion | Growth trajectory positive |
| Domestic Market | ₹60.00 billion | ₹130.00 billion |
| Global Position | 3rd largest by volume | Expanding reach |
The Council emphasized that India's growing domestic pharmaceutical market provides significant scale advantages, supply-chain resilience, and manufacturing depth that directly support export-led growth. India's position as the world's third-largest pharmaceutical producer by volume strengthens its role as a supplier of affordable, quality-assured medicines globally.
Innovation and Academic Collaboration
Discussions with Satya Prakash L., Joint Secretary of the Department of Pharmaceuticals, focused on strengthening industry-academia collaboration across multiple pharmaceutical segments. The conversations emphasized innovation, skill development, and capacity building initiatives spanning clinical research, biopharmaceuticals, vaccines, and active pharmaceutical ingredients.
Additionally, the PHARMEXCIL delegation met with Lav Aggarwal, Director General of DGFT, to discuss comprehensive trade facilitation frameworks and measures designed to accelerate exporter participation while improving ease of doing business for pharmaceutical manufacturers.
Industry Leadership Perspective
Commenting on these strategic engagements, PHARMEXCIL Chairman Namit Joshi noted that India's pharmaceutical sector stands at a pivotal inflection point, supported by strong export momentum, a rapidly expanding domestic market, and consistent policy backing from government departments.
Nipun Jain emphasized that platforms such as Chintan Shivir and iPHEX serve as critical enablers for MSMEs, helping them access global markets while fostering essential dialogue around quality standards and competitive positioning. Through these comprehensive government engagements, PHARMEXCIL reaffirmed its commitment to working closely with policy makers to accelerate exports, strengthen MSME participation, and position India as a long-term, reliable partner in the global healthcare value chain.
15
